NZ611614A - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms

Info

Publication number
NZ611614A
NZ611614A NZ611614A NZ61161411A NZ611614A NZ 611614 A NZ611614 A NZ 611614A NZ 611614 A NZ611614 A NZ 611614A NZ 61161411 A NZ61161411 A NZ 61161411A NZ 611614 A NZ611614 A NZ 611614A
Authority
NZ
New Zealand
Prior art keywords
compositions
associated symptoms
methods
amyloid plaque
plaque associated
Prior art date
Application number
NZ611614A
Other languages
English (en)
Inventor
David Holtzman
Jungsu Kim
Hong Jiang
Adam Eltorai
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NZ611614A publication Critical patent/NZ611614A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ611614A 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms NZ611614A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US201161548542P 2011-10-18 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
NZ611614A true NZ611614A (en) 2015-07-31

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611614A NZ611614A (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) * 2022-11-30 2025-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
AU2005228764A1 (en) * 2004-03-30 2005-10-13 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
WO2007098417A2 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
ZA201303996B (en) 2015-10-28
US20140037638A1 (en) 2014-02-06
US20160355581A1 (en) 2016-12-08
EP2646053A4 (en) 2014-05-28
WO2012075422A2 (en) 2012-06-07
MX2013006116A (es) 2013-10-17
RU2013130002A (ru) 2015-01-10
JP2014502276A (ja) 2014-01-30
CN103338786A (zh) 2013-10-02
WO2012075422A3 (en) 2012-10-04
SG190952A1 (en) 2013-07-31
AU2011336360A1 (en) 2013-07-04
CA2819679A1 (en) 2012-06-07
BR112013013723A2 (pt) 2019-09-24
KR20140017513A (ko) 2014-02-11
EP2646053A2 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MY163521A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2012062925A3 (en) Compounds and methods for treating pain
NZ602219A (en) Methods and compositions for treating degos’ disease
WO2011083150A3 (en) Obesity small molecules
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX355543B (es) Macrociclos peptidomiméticos.
WO2012173846A3 (en) Peptidomimetic macrocycles
SG179095A1 (en) Novel assay for the detection of amyloid beta peptides
PH12013501490A1 (en) Methods for diagnosing and treating eye-length related disorders
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
IN2015DN00370A (enExample)
WO2012075422A3 (en) Compositions and methods for treating amyloid plaque associated symptoms
GB201317446D0 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ721918A (en) Modified serpins for the treatment of bleeding disorders
WO2012170945A3 (en) Methods for modulating kallikrein (klkb1) expression
IN2014DN08385A (enExample)
WO2012019054A3 (en) Expression of antibody or a fragment thereof in lactobacillus
PH12014501061B1 (en) Tricyclic compounds, compositions comprising them and uses thereof
MX2016001384A (es) Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
IN2012DN00549A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2016 BY CPA GLOBAL

Effective date: 20151222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2017 BY CPA GLOBAL

Effective date: 20161021

LAPS Patent lapsed